Fatigue News and Research

RSS

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Biogen Idec and Elan Corporation, plc today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

13 Apr 2010

Research on efficacy of yoga in breast cancer treatment attracts award of over $4.5M

In an ongoing effort to scientifically validate the age-old belief that mind-body interventions have a beneficial impact on the health of patients, The University of Texas M. D. Anderson Cancer Center has been awarded more than $4.5 million to study the efficacy of incorporating yoga into the treatment program of women with breast cancer.

13 Apr 2010

Eclipsys introduces Sunrise Enterprise 5.5 integrated software solutions for healthcare industry

Eclipsys Corporation, The Outcomes Company® today announced the availability of Sunrise Enterprise™ 5.5 — a rich suite of integrated software solutions that serves to differentiate Eclipsys™ and its client base within the healthcare industry.

12 Apr 2010

Nationwide Asthma Screening Program to find people at risk

The American College of Allergy, Asthma and Immunology will help adults and children to find out if they are at risk for asthma through its Nationwide Asthma Screening Program. More than 200 screenings will take place across the country this year. Locate one near you on the calendar of screenings available at AllergyAndAsthmaRelief.org.

12 Apr 2010

Jazzercise, Back in the Swing USA partner to promote breast cancer survivorship programs

Jazzercise, the world's leading dance fitness program, is proud to announce its partnership with Back in the Swing USA®, a grassroots nonprofit organization exclusively dedicated to providing awareness, access and financial support for breast cancer survivorship programs and academic medical research in the field of breast cancer survivorship.

7 Apr 2010

Soccer for Health

Led by Professors Peter Krustrup and Jens Bangsbo from the Department of Exercise and Sports Sciences, University of Copenhagen, the 3-year project covered several intervention studies involving both men, women and children, who were divided into soccer, running and control groups.

7 Apr 2010

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Results from a recent survey of 400 Sjogren's syndrome patients showed that half of those surveyed experienced common symptoms such as dry mouth or dry eyes for three or more years before receiving an accurate diagnosis from a healthcare professional.

6 Apr 2010

Barrow Neurological Institute scientist receives grant to study myasthenia gravis

A scientist at Barrow Neurological Institute in Phoenix has been awarded a major grant from the Muscular Dystrophy Association to continue his groundbreaking work in the disease of myasthenia gravis.

6 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

HCM: Questions to ask

While a jury awarded Tony and Angela Key, $1.6 million following a malpractice trial in the death of their 22-year-old son, Antwoine, a basketball player for Eastern Connecticut State University who collapsed and died during a game in 2005, it is a small measure of solace when a young life is cut short, particularly when the cause - hypertrophic cardiomyopathy (HCM) - could have been treated, had it been properly diagnosed.

3 Apr 2010

Study: Trial vaccine eliminates residual cancer cells in CML patients

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

3 Apr 2010

Tips to get optimum healthcare coverage during economic downturn

The economic downturn is impacting the health of many people – not only by exacerbating conditions like hypertension, stress and fatigue, but also by causing some people to put off getting the health care they need.

3 Apr 2010

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

MDA awards 42 medical researchers and labs over $21M for critical neuromuscular research

Forty-two medical researchers and their labs have been awarded over $21 million by the Muscular Dystrophy Association to continue critical neuromuscular research. Many of the grants are multi-year awards to be dispersed over the next three years.

1 Apr 2010

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

Vidazorb probiotic supplements could minimize severity of IBS symptoms

April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.

31 Mar 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU). Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai.

31 Mar 2010

4 kg liver tumor removed from 60 year old Nigerian

A team of doctors led by Dr Ramcharan Thiagarajan, Consultant Surgical Gastroenterology & Hepato Pancreatic Biliary Surgery, Fortis Hospitals, Bangalore (formerly Wockhardt Hospitals) recently performed a high risk surgery on a 60 year old Nigerian to remove a perilous tumor weighing 4 kilos surrounding his liver.

29 Mar 2010

Fatigue News and Research

Targeted therapy MDV3100 is effective for patients with CRPC: Study

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Research on efficacy of yoga in breast cancer treatment attracts award of over $4.5M

Eclipsys introduces Sunrise Enterprise 5.5 integrated software solutions for healthcare industry

Nationwide Asthma Screening Program to find people at risk

Jazzercise, Back in the Swing USA partner to promote breast cancer survivorship programs

Soccer for Health

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Barrow Neurological Institute scientist receives grant to study myasthenia gravis

Dalfampridine drug for multiple sclerosis now available in the U.S.

HCM: Questions to ask

Study: Trial vaccine eliminates residual cancer cells in CML patients

Tips to get optimum healthcare coverage during economic downturn

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

MDA awards 42 medical researchers and labs over $21M for critical neuromuscular research

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

Vidazorb probiotic supplements could minimize severity of IBS symptoms

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

4 kg liver tumor removed from 60 year old Nigerian

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News